Introduction: Iron deficiency and iron deficiency anaemia are common complications in inflammatory bowel disease [IBD] patients. Anaemia in IBD is attributable to chronic blood loss and/or impaired iron intake and absorption. International guidelines recommend intravenous iron supplementation in IBD patients, since oral supplements are frequently poorly tolerated and can exacerbate inflammation. Clinical scores and quality of life improved due to the amelioration of anaemia symptoms. Conclusions: Ferinject®-therapy was proven to be effective and safe in a large cohort of patients with IBD-associated anaemia in routine practice. Rapid, high-dose application is convenient for physicians and reduces patients' time lost from work.
Introduction
Iron deficiency [ID] and subsequent anaemia are common complications in patients with inflammatory bowel disease [IBD] , a set of chronic intestinal conditions including Crohn's disease [CD] and ulcerative colitis [UC] which share a variety of symptoms including diarrhoea, abdominal pain, and fever, as well as extraintestinal manifestations affecting the joints, skin, and eyes. Anaemia in IBD has multiple causes, 1,2 the most prevalent being iron deficiency. 6 Iron deficiency occurs in up to 90% of IBD patients, 3 often progressively deteriorating to the point of manifest iron deficiency anaemia [IDA] , which has a major impact on quality of life in IBD patients. 4, 5 IDA is largely attributable to chronic blood loss from the ulcerated intestinal mucosa and/or to impairment of iron intake and absorption. [6] [7] [8] Symptoms of IDA include fatigue, headache, hair loss, and [exertional] dyspnoea. In addition, restless legs syndrome has been shown to occur at an approximately nine-fold higher rate in individuals with IDA than in the overall population. 9 The goals of anaemia treatment are to raise haemoglobin, serum ferritin [s-ferritin], and transferrin saturation [TSAT] levels above the lower threshold of normal [LLN] , thus not only restoring short-term haematopoietic status but also replenishing iron stores to prevent recurrence of anaemia. Iron supplementation is recommended even if iron deficiency occurs without reduction of haemoglobin concentration. 10, 11 Oral iron replacement is of limited value, failing to balance continuous iron loss due to inadequate intestinal absorption in the presence of inflammation. 2, 11 Furthermore, non-absorbed iron has been shown to enhance mucosal inflammation in animal models and increase clinical activity in IBD patients. 12, 13 In contrast, intravenous [IV] iron has been demonstrated to be safe, effective, and well tolerated in both the correction of IDA and the maintenance of iron stores in patients with IBD. 12, 14, 15 Moreover, intravenous iron replacement not only facilitates the faster correction of ID and repletion of body iron stores, but also effectively avoids gastrointestinal [GI] side effects by bypassing the GI tract. Several intravenous iron preparations are currently available for treatment of IDA. Such formulations differ by complex chemistry and can be grouped into labile, semi-labile, and stable iron complexes. 16, 17 Of all the IV iron compounds available, by far the largest number of pharmacology studies, phase I to III clinical trials, and controlled clinical trials in IBD patients have been performed with ferric carboxymaltose [FCM] . [18] [19] [20] [21] These trials have proved its efficacy and tolerability in IBD-associated anaemia. No safety concerns have been identified. However, published data concerning routine use in daily practice are still limited. This post-marketing surveillance study was designed and performed to assess the safety and efficacy of FCM in a large cohort of patients under routine daily conditions.
Materials and Methods

Study design
This non-interventional study [NIS] was designed as a prospective, multicentre survey without influence on regular treatment of patients by the attending physician in routine medical care. Physicians [hospital gastroenterologists, specialists in internal medicine, and general practitioners] in 101 German treatment centres were recruited to enrol patients and to complete treatment documentation according to the study protocol. Due to the non-interventional character of the study, subjects were treated based on the medical needs of their underlying disease in accordance with therapy requirements published in the German Physicians' Circular [GPC]. 
Patient characteristics and definitions
Patients at 101 treatment centres who were due to receive iron replacement therapy with ferric carboxymaltose, based on the indication and therapy requirements according to the GPC and Summary of Product Characteristics [age ≥18 years, iron deficiency anaemia based on chronic IBD, therapeutic necessity for IV iron substitution], were invited to participate in the observational study; 223 patients gave written informed consent and were enrolled in the study. All patients were FCM-naïve.
Intervention
The patients received FCM according to the usual therapeutic procedure of the attending physician and in accordance with the authorised indications of the Summary of Product Characteristics for ferric carboxymaltose. Mean number of infusions given during the observation period was 3.3 [range 1-10].
Efficacy and safety analysis
The primary efficacy endpoint was response to treatment, defined as correction of anaemia (haemoglobin [[Hb] ≥13 g/dL in men and ≥12 g/dL in women) or Hb increase of 2 g/dL or more. Partial response was defined as Hb increase of 1 g/dL or more but less than 2 g/dL, without anaemia correction.
Secondary analyses included normalisation of serum ferritin [s-ferritin] and serum transferrin saturation [TSAT] and predictive values to treatment response according to gender, age, and baseline measurements of iron parameters.
For the analysis of efficacy parameters, all available data were used. Clinical signs/symptoms associated with anaemia were analysed according to a self-devised 'symptom scale' by shift tables comparing beginning of study [BOS] and end of study [EOS] 24 Collected data were analysed and reported by SAS software [Version 9.2]. The analysis was performed in an exploratory manner using descriptive statistical methods. For the valuation of differences, a two-sided Student's t-test, with α = 0.05, was adopted.
Data from premature study termination visits between Weeks 4 and 12 after inclusion were accounted to the visit week in which they actually occurred. Termination visits at Week 12, 13, or 14 were accounted to Week 12. For these patients, changes from baseline to last recorded value were analysed. Other patients were considered not evaluable. 
Results
Patients and treatments
Exposure to [dosing of] iron
A total of 495 intravenous FCM treatment courses were given to 193 IBD patients. Due to the non-interventional nature of the study, dose calculations and infusion regimens were determined by the treating physicians purely according to the patients' medical needs and in the context of regular clinical practice. Median total FCM dosage of the 150 patients in the efficacy group was 975 mg, with total doses ranging from 100 mg to 4800 mg. FCM was most commonly administered at cumulative doses of between 500 mg and 2000 mg [76.7%] [7.3% received <500 mg, 9.3% received 2000-3000 mg, and 6.7% received >3000 mg]. The mean minimum single dose per patient was 431 ± 301.65 mg, and the mean maximum single dose was 508 ± 321.01 mg. In the efficacy group, 13 subjects received additional concomitant anti-anaemic treatment with oral iron compounds. The response in patients receiving oral iron was, however, not significantly different from patients treated with Ferinject® only [results not shown].
Concerning number of infusions, 1-10 infusions were applied to the patients in the efficacy group, with a median value of two infusions. The median time period from first to last infusion was 22 Figure 2a . In all subgroups, the mean increase in Hb was statistically significant. [data not shown]. These improvements were sustained for the whole observation period and resulted in a greater mean difference of 3.1 g/dL in subjects with low baseline Hb values compared with 1.7 g/dL in subjects with higher baseline Hb [data not shown]. Mean Whereas at BOS, mean CRP levels were outside normal range, they were found to decrease during FCM therapy independently of baseline Hb levels [data not shown]. The change in CRP levels from BOS to EOS was statistically significant overall, as well as in patients with high disease activity, in CD and UC patients treated with a total dose of 500 to 1000 mg iron, and in patients who completed therapy. The decrease in disease activity indicated by lower CRP levels was confirmed by a reduction in mean values of the clinical disease activity indices CDAI and CAI [data not shown].
Serum ferritin and transferrin saturation
Patients in both CRP subgroups showed increases in Hb, serum ferritin, and TSAT. CRP and the number of symptoms decreased from baseline to end of study [ Table 2 ].
Clinical [non-haematological] parameters
In order to assess the influence of IV iron treatment on their general well-being, patients were asked at BOS and EOS to evaluate the following anaemia-associated, clinical, non-haematological parameters for intensity, by rating them on a 'symptom' scale of 0 for 'not present' to 4 for 'very severe': fatigue, lack of concentration, headache, paleness of mucous membranes, hair loss, [exertional] dyspnoea, sleeping disorders, and restless legs syndrome. Whereas 146 patients [97%] reported at least one non-haematological symptom at baseline, 14 patients [9.3%] reported all eight symptoms. The average number of symptoms per patient at baseline was 4.7 ± 0.3. At EOS, this figure had significantly declined, with patients reporting an average of 3.0 ± 0.3 symptoms [p <0.001]. Furthermore, 14.7% of patients [22] were symptom-free, with only one patient reporting the presence of all symptoms.
The most frequent symptom at baseline was 'fatigue', with 93% of patients reporting at least mild symptoms, and the rarest was 'restless legs syndrome' with 22%. For each of the symptoms, the number of affected patients decreased from BOS to the EOS, the most evident decreases being associated with paleness of mucous membranes, followed by [exertional] dyspnoea and lack of concentration [ Figure 3 ].
The mean intensity of reported non-haematological symptoms at baseline varied between 1. 
Predictive factors for response to intravenous iron
Logistic regression analyses of the current data were performed. However, after removal of excess values and missing data, the sample size was too small to allow the identification of any predictors of response.
Safety
Among the 193 patients representing the safety population, only one adverse event was reported, an aggravation of UC. This exacerbation was estimated by both physician and sponsor to be a serious adverse event [SAE] , but the treating physician judged it to be unrelated to 
Discussion
Iron deficiency [ID] is the main cause of anaemia in IBD patients. ID arises due to dietary restrictions, malabsorption, intestinal bleeding, and/or undertreatment of anaemia. 3 Oral iron replacement is often unsuitable for anaemia therapy in IBD patients because of intolerance to oral iron compounds, abnormal absorption due to inflammation, non-compliance, and large iron deficits, all factors which limit the success of oral iron treatment for anaemia. 7, 8 The literature indicates that high doses of iron are often required in anaemic patients, with IBD patients requiring up to 3600 mg daily, 4 and several international guidelines recommend the administration of intravenous iron formulations in preference to oral iron in the correction of IBDassociated anaemia. 10, 25, 26 Nevertheless, a retrospective analysis of clinical practice in nine European countries in 2011 found that oral iron was administered to 68% of IBD patients with anaemia [with national rates varying from 24% to 83%], but only 32% [16% to 79%] received intravenous iron therapy. 27 Our results underline that awareness of international guidelines on anaemia and iron therapy in IBD is still lacking, as evidenced by the very wide total dose range of 100 mg to 4800 mg. Furthermore, the fact that dose duration was longest not only for the largest, but also for the smallest doses [<500 mg] indicates that there is still some trepidation among physicians concerning the application of intravenous iron in general.
FCM therapy has been demonstrated to be very effective and convincingly safe in IBD-associated anaemia in a large cohort of patients under daily routine conditions, and has also been shown to sufficiently replenish iron stores. In this NIS, all goals of anaemia treatment were met in the majority of patients: to increase Hb to normal levels or by at least 2 g/dL, and to raise serum ferritin and transferrin saturation above the lower limit of normal.
Our results from daily routine practice confirm the results obtained in two pivotal clinical trials with FCM, 18, 19 covering an equally sized but selective and strictly-defined IBD patient collective. In these controlled trials, median Hb increased from 8.7 to 12.3 g/dL. Increments of Hb increase were found to be greatest at the second [and third] visit.
Mean ferritin level in this NIS increased from 52 μg/L to 103 μg/L. Again, the ferritin increase [+51 μg/L] was most pronounced after Visit 2. This evidence of early response [Visit 2] is in agreement with previous FCM trials showing full response after 4-8 weeks. 18, 19 CRP levels showed a significant decrease during the observation period, falling from 6.4 mg/L to 3.5 mg/L in mean values [median 1.9 to 1.0 mg/L], indicating a general reduction in inflammatory activity. A corresponding decrease of CRP was not described in the two randomized controlled trials [RCTs] . 18, 19 However, a similar reduction in disease activity has previously been shown by Kaltwasser et al. during IV iron sucrose therapy of patients with rheumatoid arthritis and anaemia of chronic disease. The authors observed not only a slight overall reduction in CRP levels during IV iron treatment, but also significant decreases in several clinical disease activity variables. 28 In the present study, multivariate analysis was performed in an attempt to assess any relation between intravenous iron therapy and inflammation parameters. However, after removal of excess values and missing data, the sample size was too small to allow a meaningful analysis. Nevertheless, FCM does not appear to prevent drug-induced amelioration of inflammation. Larger, well-designed, prospective studies are needed in order to identify clinical, demographic, or other predictors of response to intravenous iron therapy, and to investigate further the question of whether intravenous iron therapy may influence inflammation parameters.
Shifts of clinical parameters during the observation period, particularly regarding fatigue, lack of concentration, and anaemic mucosa, indicated a tendency for clinical improvement during FCM treatment and reflect improvement in quality of life. Accordingly, acceptance of FCM therapy was high: 95% of patients assessed it to be superior to their previous substitution therapy and 79% preferred it to their previous parenteral therapy. Only one participant graded the current therapy to be inferior to the previous one, and the remaining subjects were reported as undetermined.
Single doses of 1000 mg FCM were tolerated under routine daily practice conditions by a high proportion [21 Until now, tolerability data from FCM therapy have been available from selected patient collectives in controlled clinical trials. [18] [19] [20] [21] About 57% of those patients experienced an AE and 29% an adverse drug reaction. Adverse events assessed to be clearly drug-related were mild erythematous rash, urticaria, and pruritus. However, no immunological reactions were encountered on re-challenge. It may be perceived as a limitation of the present study that no data were collected regarding changes in serum phosphate levels in patients treated with intravenous iron. Although isolated cases of symptomatic hypophosphataemia have been reported in patients receiving long-term FCM, iron polymaltose, and iron sucrose therapy, no serious AEs associated with hypophosphataemia were recorded in any of the large clinical trials of intravenous iron preparations. However, FCM seems to be associated with a higher risk of hypophosphataemia compared to other IV iron products. Although the mechanisms involved are not yet fully understood, 29 limited data indicate that FCM-associated hypophosphataemia may be dose-dependent. 30 Thus, serum phosphate values should be routinely monitored, especially in patients with low baseline phosphate values or other concomitant risk factors [e.g. vitamin D deficiency, renal tubular defects], and in those receiving long-term or repeated intravenous iron therapy. 31 Reporting data from a prospective open non-interventional trial including 394 Swedish IBD patients from 14 centres, Befrits et al. describe 27 [7%] infusion reactions [most commonly pruritus, chest tightness, nausea, and slightly increased temperature] of which, however, only one was considered serious. 32 In their recent network meta-analysis comparing efficacy and safety of IV iron compounds based on five trials in IBD patients, Aksan et al. found that 12% of patients reported adverse events in connection with FCM doses of 500-1000 mg, but all but one [pulmonary embolism] were minor and transient in nature. 33 In contrast, during the 495 routine FCM applications discussed in this NIS, only one adverse event [0.5%] was monitored. As classified by MedDRA terminology, it was a gastrointestinal disorder [SOC] , more precisely the deterioration of ulcerative colitis [PT] . This AE was not related to the therapy in question. Reasons for the obvious difference in tolerability between controlled enquiry and routine application remain unknown, and it is conceivable that some AEs were lost from the analysis due to missing patient data. However, our data have only recently been substantiated by the results of a contemporaneous Spanish trial 34 which reports only one severe AE during 88 FCM infusions in 72 patients. Whereas it may be argued that the disparity is a result of more intensive monitoring in clinical trials compared with non-interventional studies, this remains hypothetical. Generally, however, the tolerability of FCM therapy can be described as excellent under regular day-to-day treatment conditions. In addition, data from routine practice provides important information for the advancement of therapeutic treatment strategies and for the updating of guidelines.
Summary and Conclusion
Ferinject® therapy was proven to be effective and safe in a large cohort of patients with IBD-associated anaemia in routine practice. Rapid, high-dose application is convenient for physicians and reduces patients' time lost from work.
In this retrospective study analysing real-life data from IBD patients treated with FCM, clinical scores and quality of life improved due to the amelioration of anaemia symptoms. Nevertheless, there are still a number of important issues which need to be addressed in future studies, in particular concerning the long-term safety of high doses of intravenous iron and the utility of remission therapy to ensure and sustain normal haemoglobin and ferritin levels and to maintain patient quality of life.
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